Highest-materiality recent filing
Hawthorne had net sales of $130.2M and net loss of $9.6M for fiscal year ended Sept 30, 2025.
Vireo Growth to acquire C21 Investments in all-stock deal; exchange ratio 0.023052
Each C21 share exchanged for 0.023052 Vireo subordinate voting shares; C21 shareholders to vote in Q3 2026.
Eaze FY2025 net loss $24.1M on $141M revenue; Vireo merger closed Apr 1, 2026
Eaze FY2025 revenue $141.1M; gross profit $59.0M (41.8% margin).
Vireo Growth closes $13.66M Bridgewell acquisition; plans Nevada and Maryland dispensary buys
Closed Bridgewell acquisition for ~$13.66M in convertible notes; converts after 2 years into ~22M shares at $0.62/share.
Vireo Growth acquires NY cannabis facility from IIP for $88.5M with $49M seller note and $41M loan
Purchased 389,000 sq ft cultivation/production facility in Perth, NY from IIP-NY 2 LLC for $88.5M.
Vireo Growth Q1 revenue $106.2M (+333.5% YoY); closes multiple acquisitions
GAAP revenue $106.2M, up 333.5% YoY; GAAP gross profit $59.3M (55.8% margin).
Vireo Growth to acquire FLUENT in all-stock deal; exchange ratio 0.0705359
FLUENT shareholders receive 0.0705359 Vireo shares per share; transaction structured as court-approved plan of arrangement under Ontario law.
Vireo Growth acquires Hawthorne Gardening, gains $110M cash+NWC, pays 213M shares + 80M warrants
Vireo issued 213M shares (deemed $0.60) and 80M warrants ($0.85 strike) to Good Dog (Scotts designee) for Hawthorne.
Closed Eaze merger on April 1; issued 90.4M shares at $0.56 per share (base consideration $47.04M).
Vireo Growth delivers 90.7M shares into escrow for PharmaCann asset deal; closing expected Q2'26
MSA with PharmaCann effective March 22, 2026; Vireo to manage Colorado retail assets until closing.
Vireo Growth closes acquisition of Schwazze's 45 dispensaries and 2 manufacturing facilities
Acquired 24 Colorado dispensaries, 21 New Mexico dispensaries, and one manufacturing facility in each state.
Vireo Growth Q4 revenue $104.5M (+318% YoY); pro forma same-store sales +22%
Q4 GAAP revenue $104.5M, up 317.7% YoY; gross profit margin 54.4% vs 50.6%.
Vireo Growth acquires Eaze for ~$47M in stock, expanding to CA, FL, CO
Base consideration ~$47M in ~84M subordinate voting shares at $0.56 per share.
Acquiring ~$2.6M face value (principal + interest) of Schwazze's 13% Senior Secured Convertible Notes for ~$1.6M in subordinate voting shares at $0.54/share.
Vireo Growth to acquire 17 Colorado dispensaries from PharmaCann for ~$49M in shares
Vireo enters APA to buy 17 Colorado dispensaries from PharmaCann; total consideration ~$49M in Vireo subordinate voting shares plus liability assumption.
Vireo Growth wins $111M credit bid for Schwazze assets, forms NewCo
Vireo subsidiary credit bid ~$111M of Schwazze 13% Senior Secured Notes, winning asset sale.
Vireo Q3 revenue jumps 264% YoY to $91.7M; adjusted EBITDA $25.4M
GAAP revenue of $91.7M (+264% YoY); GAAP gross profit $37.4M (40.8% margin, down 820 bps).
Vireo Growth settles litigation with Verano for ~US$10M in assets and cash
Settlement dismisses all outstanding litigation between Vireo and Verano in British Columbia Supreme Court.
Acquired ~$91M face value (principal + interest) of Schwazze's 13% Senior Secured Notes for ~$62M in 114.8M subordinate voting shares at $0.54/share.
Vireo Growth to acquire ~86% of Schwazze's senior secured notes for $62M in stock
Acquiring ~86% of Schwazze's 13% Senior Secured Convertible Notes due Dec 2026 for ~$62M in subordinate voting shares.
Vireo Q2 GAAP revenue $48.1M (+91% YoY); operating loss of $2.0M vs prior profit
GAAP revenue $48.1M (+91% YoY); gross profit $20.4M (+50%). Gross margin fell 1,150 bps to 42.5%.
Vireo Growth files Q1 2025 unaudited financials for acquired Proper Holdings and Deep Roots
Proper Holdings net sales $21.4M in Q1 2025, down from $23.0M in Q1 2024.
Vireo closes $153M refinancing; expects $10M+ annual interest savings
Closed $120M first lien term loan at 8.3% interest with bank syndicate; oversubscribed.
Vireo Growth pro forma Q2 2025 revenue guidance $88-91M; expects >$100M cash after debt refinancing
Pro forma Q2 2025 revenue expected $88-$91M, adjusted EBITDA $23-$24M, assuming mergers closed April 1.
Vireo closes $132.7M acquisition of Nevada cannabis operator Deep Roots; 255.2M shares issued
Consideration 255.2M Vireo shares at $0.52/share; multiple 4.175x 2024 Closing EBITDA of $30M.
Vireo Growth closes $102M acquisition of Proper Brands in Missouri
Total consideration $102M paid with 196.2M subordinate voting shares at $0.52 reference price.
Vireo closes $69.8M WholesomeCo & Arches acquisition; issued 134.2M shares at $0.52
Total consideration of $69.8M paid in 134.2M subordinate voting shares at $0.52 reference price.
Vireo Growth Q1 revenue $24.5M (+1.9% YoY); Adjusted EBITDA $6.6M (+8.5%); merger close expected Q2
GAAP revenue $24.5M (+1.9% YoY); gross profit margin 50.6% (flat YoY).
Vireo Growth amends merger agreements for Proper, Deep Roots, Wholesome; shareholders approve deals
Amendments adjust earnout calculation (greater of $37.5M or 5x revenue minus $4M) and soften forfeiture triggers.
Vireo Growth FY2024 revenue $99.4M (+15.4%); adjusted EBITDA $25.1M (+28.4%)
Record FY2024 revenue of $99.4M (ex-discontinued ops +15.4% YoY); gross margin expanded 110 bps to 51.1%.
Vireo Growth closes oversubscribed $81M equity offering at $0.625/share
Closed on Dec 30, 2024, issuing 129.5M subordinate voting shares at US$0.625 each, a 16.8% premium to the Dec 27 OTCQX close.
Vireo Growth enters $26.5M in secured credit facilities for Minnesota cultivation buildout
Chicago Atlantic Credit Agreement: up to $11.5M ($5.5M funded at close); 10.5% interest, maturity June 26, 2026.
Vireo Growth to acquire Deep Roots, Proper, WholesomeCo for shares at $0.52 reference price
All-share mergers with Deep Roots (Ref. EBITDA $31M), Proper ($31M), and WholesomeCo ($16M) at $0.52/share reference price.
Vireo Growth secures $10M convertible debt facility with 12% interest, $0.625 conversion
Up to $10M convertible notes; maturity Nov 1, 2027; cash interest 12% paid monthly.
Vireo Growth CEO Joshua Rosen resigns; Amber Shimpa appointed CEO; terminates Grown Rogue agreement
Joshua Rosen resigns as CEO, interim CFO, and director; receives 500k RSUs, 500k options, salary continuation $300k/yr for 2 years.
Vireo Growth extends credit facility to Jan 2027; converts $10.5M notes into 73M shares
Ninth Amendment extends credit facility maturity to Jan 29, 2027, waives default on NY disposition, extends deadline to July 31, 2025.
Goodness Growth appoints Josh Rosen permanent CEO; extends credit to June 14, 2024
Josh Rosen, formerly Interim CEO and CFO, appointed CEO effective May 1, 2024; will continue as Interim CFO.
Goodness Growth enters binding LOI to sell VireoNY assets to ACE for $3-5M; closes by June 30
Purchase price $3-5M for VireoNY licenses, inventory, assets; ACE assumes IIP lease for Johnstown campus.
In connection with Mr. Mazarakis’ appointment as Co-Executive Chairman and Chief Executive Officer of the Company, the Company issued to Mr. Mazarakis 19,000,000 RSUs settled in Parent Shares (the “Time-Vested RSUs”).
In connection with Mr. Macdonald’s appointment as Chief Financial Officer of the Company, the Company issued to Mr. Macdonald 9,500,000 Restricted Stock Units settled in Parent Shares (the “Time-Vested RSUs”).
On October 10, 2024, Amber Shimpa, age 45, was appointed Chief Executive Officer of the Company.
On October 10, 2024, Joseph Duxbury, age 32, was appointed interim Chief Financial Officer of the Company.
On October 10, 2024, Joshua Rosen, Chief Executive Officer, Interim Chief Financial Officer and Director of the Company resigned from all of his positions with the Company.
Patrick Peters, Executive Vice President of Retail of Vireo Health, Inc., a wholly-owned subsidiary of Goodness Growth Holdings, Inc. (the “ Company ”), informed the Company of his intention to resign from his position effective June 14, 2024.
On May 1, 2024, the Board of Directors of the Company appointed Josh Rosen, 51, currently serving as Interim Chief Executive Officer, Interim Chief Financial Officer and Director of the Company, as Chief Executive Officer of the Company, effective immediately.
John Heller, Chief Financial Officer of the registrant, is resigning his employment effective September 30, 2023.
On March 31, 2023, the Company announced that Chelsea Grayson and Amber Shimpa had resigned their respective positions as members of the Company’s board of directors.
On March 31, 2023, the Company announced that Chelsea Grayson and Amber Shimpa had resigned their respective positions as members of the Company’s board of directors.
Dr. Kyle E. Kingsley, age 47, has been appointed to the position of Executive Chairman and has resigned the position of Chief Executive Officer
On February 14, 2023, the Registrant announced the appointment of Joshua Rosen, age 49, as interim CEO of each of the Registrant and VHI.
Max materiality 1.00 · Median 0.75 · Most common event m_and_a